AR122427A1 - POLYMERIC EXCIPIENTS FOR BIOPHARMACEUTICAL FORMULATIONS - Google Patents

POLYMERIC EXCIPIENTS FOR BIOPHARMACEUTICAL FORMULATIONS

Info

Publication number
AR122427A1
AR122427A1 ARP210101041A ARP210101041A AR122427A1 AR 122427 A1 AR122427 A1 AR 122427A1 AR P210101041 A ARP210101041 A AR P210101041A AR P210101041 A ARP210101041 A AR P210101041A AR 122427 A1 AR122427 A1 AR 122427A1
Authority
AR
Argentina
Prior art keywords
polymeric excipients
copolymer
biopharmaceutical formulations
peptides
proteins
Prior art date
Application number
ARP210101041A
Other languages
Spanish (es)
Inventor
Eric A Appel
Caitlin Maikawa
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of AR122427A1 publication Critical patent/AR122427A1/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Un copolímero a base de poliacrilamida reduce o evita la agregación de proteínas y péptidos en las formulaciones acuosas en las interfaces hidrofóbicas, de este modo aumenta la estabilidad térmica de proteínas y péptidos en la formulación. Los métodos y las composiciones que comprenden el copolímero y una proteína o el copolímero e insulina se pueden usar para tratar afecciones que incluyen diabetes.A polyacrylamide-based copolymer reduces or prevents aggregation of proteins and peptides in aqueous formulations at hydrophobic interfaces, thereby increasing the thermal stability of proteins and peptides in the formulation. The methods and compositions comprising the copolymer and a protein or the copolymer and insulin can be used to treat conditions including diabetes.

ARP210101041A 2020-04-17 2021-04-19 POLYMERIC EXCIPIENTS FOR BIOPHARMACEUTICAL FORMULATIONS AR122427A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063011928P 2020-04-17 2020-04-17

Publications (1)

Publication Number Publication Date
AR122427A1 true AR122427A1 (en) 2022-09-07

Family

ID=83444600

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210101041A AR122427A1 (en) 2020-04-17 2021-04-19 POLYMERIC EXCIPIENTS FOR BIOPHARMACEUTICAL FORMULATIONS

Country Status (1)

Country Link
AR (1) AR122427A1 (en)

Similar Documents

Publication Publication Date Title
CO2022014566A2 (en) Polymeric excipients for biopharmaceutical formulations
AR039688A1 (en) ACID INSULIN PREPARATIONS WITH IMPROVED STABILITY
DE602006014990D1 (en) INTRANASAL ADMINISTRATION OF FAST-ACTING INSULIN
BR112021002069A2 (en) Composition for hair treatment, methods and uses.
ECSP19018654A (en) ANTIBODIES AGAINST DENGUE VIRUS, POLYPEPTIDES CONTAINING VARIANT HR REGIONS, AND METHODS OF USE
PE20211469A1 (en) STABILIZED RSV PREFUSION PROTEINS F
GT201200069A (en) VERY CONCENTRATED PHARMACEUTICAL FORMULATIONS
EA201791333A1 (en) GLUCAGON DERIVATIVES WITH IMPROVED STABILITY
CL2020002252A1 (en) Ophthalmic formulation.
MA43686B1 (en) Stable liquid formulation of gonadotropins
CO2018000768A2 (en) Intravenous administration of citrulline during surgery
PE20090653A1 (en) IMMUNOGENIC FORMULATION, BECAUSE IT INCLUDES AN ATTENUATED RECOMBINANT STRAIN OF MYCOBACTERIUM, PREFERENTIALLY THE RECOMBINANT STRAIN BACILO DE CALMETTE AND GUERIN (BCG), WHICH EXPRESSES AT LEAST ONE PROTEIN OR RESPIRATORY IMMUNOGENIC FRAGMENT OF THE VIRUS
AR122427A1 (en) POLYMERIC EXCIPIENTS FOR BIOPHARMACEUTICAL FORMULATIONS
BR112022004674A2 (en) Camphorsulfonic acid and combinations thereof with cationic excipients as viscosity reducing agents in highly concentrated protein formulations
AR115790A1 (en) SOLUBILIZED APIRASES, METHODS AND USES
CO2023000239A2 (en) Viscosity reducing excipients and combinations thereof for highly concentrated protein formulations
AR128464A1 (en) DUAL GLP-1 AND GLUCAGON AGONIST PEPTIDES WITH IMPROVED BIOLOGICAL STABILITY
UY39503A (en) SOLID FORMULATION
DK1341813T3 (en) Use of L-carnitine as a stabilizer of proteins
CO2021011057A2 (en) Cosmetic / dermatological composition
BR112022003751A2 (en) Hemoglobin analogues cross-linked with thiosuccinyl and methods of use and preparation thereof
BR112022009522A2 (en) VOXELOTOR ADMINISTRATION METHODS
BR112021026752A2 (en) Pharmaceutical composition, conjugate comprising a fusion protein, method of production and use thereof
DOP2024000016A (en) ACTRII PROTEINS AND USES THEREOF
CO2019010902A1 (en) Liquid pharmaceutical composition containing dantrolene sodium